The effect of low-dose aspirin on serum placental growth factor levels in a high-risk PREDO cohort

• Published in: Pregnancy hypertension Vol. 13; pp. 51 - 57
• Main Authors: Murtoniemi, K., Vahlberg, T., Hämäläinen, E., Kajantie, E., Pesonen, A.K., Räikkönen, K., Taipale, P., Villa, P.M., Laivuori, H.
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.07.2018
• Subjects: Administration, Oral; Adult; Aspirin; Aspirin - administration & dosage; Aspirin - therapeutic use; Cohort Studies; Female; Finland - epidemiology; Gestational Age; Humans; Longitudinal Studies; Low-dose acetylsalicylic acid; Placenta Growth Factor - blood; Placental growth factor; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - therapeutic use; Pre-eclampsia; Pre-Eclampsia - blood; Pre-Eclampsia - drug therapy; Pre-Eclampsia - epidemiology; Pregnancy; Risk Factors; Treatment Outcome; Aspirin; Low-dose acetylsalicylic acid; ANOVA; LDA; Pre-eclampsia; mmHg; Placental growth factor; MAP; PlGF; Uta-PI; BMI
• ISSN: 2210-7789; 2210-7797
• DOI: 10.1016/j.preghy.2018.04.003

Our first aim was to study the longitudinal changes of serum placental growth factor (PlGF) concentration between 12+0 and 28+0 weeks of gestation in the prospective PREDO cohort. Our second aim was to study the effect of low-dose acetylsalicylic acid (LDA; 100 mg/day), started before the 14th week of gestation, on PlGF concentration. Blood samples were collected at 12+0–14+0, 18+0–20+0 and 26+0–28+0 weeks of gestation in 101 women without and 309 with clinical risk factors for pre-eclampsia. Risk-women were divided into two groups: to those who had medium risk for pre-eclampsia and to those who had high risk for pre-eclampsia. Finally there were seven groups according to risk, treatment (no prevention/placebo/LDA) and outcome measure pre-eclampsia. Longitudinal changes in the PlGF concentration between groups were compared. To investigate the effect of LDA on serum PlGF concentration, placebo (N = 62) and LDA (N = 61) groups were compared. A repeated measures ANOVA was used to analyze differences in PlGF levels between the groups. The increase in serum PlGF concentration was higher in LDA than in placebo group (time × group effect, p = 0.046). The increase in serum PlGF concentration during pregnancy was lower in high-risk women who had placebo and developed pre-eclampsia and in medium-risk women who developed pre-eclampsia compared to the other women (time × group effect, p < 0.001). There were no differences in PlGF change between low-risk women, medium-risk women who did not develop pre-eclampsia, high-risk women in the placebo group without pre-eclampsia and high-risk women in the LDA group with and without pre-eclampsia (p = 0.15). Our finding suggests an association between LDA started before 14 weeks of gestation and higher increase in serum PlGF concentration.